Comparations of efficacy and safety of rituximab, calcineurin inhibitors and cyclophosphamide in primary membranous nephropathy: a single-center retrospective analysis

被引：0

作者：

Luying Lu ^{[1
]}

Shasha Cai ^{[1
]}

Huayan Zhu ^{[2
]}

Guangjun Liu ^{[1
]}

Yaomin Wang ^{[3
]}

Pingping Ren ^{[1
]}

Lan Lan ^{[1
]}

Xiaoqi Shen ^{[1
]}

Liangliang Chen ^{[1
]}

Ying Xu ^{[1
]}

Jun Cheng ^{[1
]}

Xiayu Li ^{[1
]}

Jianghua Chen ^{[1
]}

Fei Han ^{[1
]}

机构：

[1] Zhejiang University School of Medicine,Kidney Disease Center, The First Affiliated Hospital

[2] The First People’s Hospital of Wenling,Department of Nephrology

[3] The First People’s Hospital of Huzhou,Department of Nephrology

来源：

BMC Nephrology | / 25卷 / 1期

关键词：

Primary membranous nephropathy; Calcineurin inhibitor; Cyclophosphamide; Rituximab;

D O I：

10.1186/s12882-024-03912-4

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Efficacy analysis of rituximab in treating patients with primary membranous nephropathy dependent on calcineurin inhibitors
Li, Zhuo
Zhao, Tingting
Zhang, Shasha
Huang, Jing
Wang, Honggang
Sun, Yujiao
Wang, Rong
Chen, Bing
FRONTIERS IN IMMUNOLOGY, 2024, 15
[2] Comparison of Outcomes Between Rituximab and Cyclophosphamide for Primary Membranous Nephropathy: A Single Center Experience
Hussain, Azm U.
Sarween, Nadia
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2022, 33 (11): : 502 - 502
[3] Rituximab for the treatment of membranous nephropathy: a single-center experience
Rigler, Andreja Ales
Jerman, Alexander
Orsag, Alesa
Kojc, Nika
Kovac, Damjan
Skoberne, Andrej
Borstnar, Spela
Haler, Zeljka Veceric
Avgustin, Nusa
Kveder, Radoslav
Ferluga, Dusan
Vizjak, Alenka
Lindic, Jelka
CLINICAL NEPHROLOGY, 2017, 88 : S27 - S31
[4] A multicenter retrospective study on comparing the efficacy and safety of the therapy of intermittent cyclophosphamide and corticosteroids versus rituximab for primary membranous nephropathy
Wang, Yi
Ma, Xiaoyan
Yang, Xinyu
Bai, Shoujun
Zang, Xiujuan
Liao, Lin
Wang, Yakun
Lv, Zexin
Zhang, Ting
Zhuang, Shougang
Liu, Na
RENAL FAILURE, 2024, 46 (02)
[5] The Safety and Efficacy of Rituximab-Based Regimen in Atypical Membranous Nephropathy: A Single Center Retrospective Cohort Study
Liu, Yanan
Zhang, Shuo
Hu, Rongrong
Li, Chao
Chen, Gang
Shi, Xiaoxiao
Liu, Yan
Zheng, Ke
Li, Hang
Wen, Yubing
Li, Xuemei
Li, Xuewang
Xia, Peng
Qin, Yan
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 1983 - 1993
[6] Efficacy and safety of rituximab for primary membranous nephropathy with different clinical presentations: a retrospective study
Zhang, Shasha
Huang, Jing
Dong, Jianwei
Li, Zhuo
Sun, Mengyao
Sun, Yujiao
Chen, Bing
FRONTIERS IN IMMUNOLOGY, 2023, 14
[7] The efficacy and safety of ripertamab (SCT400) in the treatment of primary membranous nephropathy: a single center retrospective study
Yang, Xiao
Tang, Bihui
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
[8] The efficacy and safety of ripertamab (SCT400) in the treatment of primary membranous nephropathy: a single center retrospective study
Yang, Xiao
Tang, Bihui
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I2052 - I2053
[9] Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis
Zhu, Lin-bo
Liu, Lin-lin
Yao, Li
Wang, Li-ning
DRUGS, 2017, 77 (02) : 187 - 199
[10] Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis
Lin-bo Zhu
Lin-lin Liu
Li Yao
Li-ning Wang
Drugs, 2017, 77 : 187 - 199

← 1 2 3 4 5 →